The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a noninferiority, randomized, phase IIIb trial
Conclusions:
Noninferiority of mirabegron compared with solifenacin for reduction in micturition frequency could not be demonstrated in this population of OAB patients who were dissatisfied with previous antimuscarinic therapy due to lack of efficacy. Both mirabegron and solifenacin improved key OAB symptoms with no statistically significant differences observed between the two treatments. Both drugs were well tolerated.
Source: Therapeutic Advances in Urology - Category: Urology & Nephrology Authors: Batista, J. E., Kolbl, H., Herschorn, S., Rechberger, T., Cambronero, J., Halaska, M., Coppell, A., Kaper, M., Huang, M., Siddiqui, E., on behalf of the BEYOND study group Tags: Original Research Source Type: research
More News: Incontinence | Overactive Bladder | Overactive Bladder Syndrome | Statistics | Study | Urology & Nephrology | VESIcare